Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Robert Klempfner, Jonathan Leor, Alexander Tenenbaum, Enrique Z Fisman, Ilan Goldenberg, Robert Klempfner, Jonathan Leor, Alexander Tenenbaum, Enrique Z Fisman, Ilan Goldenberg

Abstract

Background: Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available.

Design: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels, matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period.

Discussion: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.

Figures

Figure 1
Figure 1
Figure 1 Study design and flow.

References

    1. Horsdal HT, Søndergaard F, Johnsen SP, Rungby J. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study. Pharmacoepidemiol Drug Saf. 2011;20:331–337. doi: 10.1002/pds.2097.
    1. Corley BT, Davenport C, Delaney L, Hatunic M, Smith D. Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. Diabet Med. 2011;28:876–879. doi: 10.1111/j.1464-5491.2010.03226.x.
    1. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S. et al.Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–1418. doi: 10.1056/NEJMoa1003795.
    1. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R. et al.Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis. Circulation. 2011;124(21):2338–2349. doi: 10.1161/CIRCULATIONAHA.111.041418.
    1. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089–2112. doi: 10.2165/11206370-000000000-00000.
    1. Yin M, Silljé HHW, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10:85. doi: 10.1186/1475-2840-10-85.
    1. Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, Szklo M, Herrington DM, Jacobs DR. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2010;209:226–229. doi: 10.1016/j.atherosclerosis.2009.08.037.
    1. Tretjakovs P, Jurka A, Bormane I, Mackevics V, Mikelsone I, Balode L, Reihmane D, Stukena I, Bahs G, Aivars JI. et al.Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. Eur J Internal Med. 2009;20:712–717. doi: 10.1016/j.ejim.2009.08.004.
    1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG. et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207. doi: 10.1056/NEJMoa0807646.
    1. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN. et al.Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42:663–669. doi: 10.1055/s-0030-1255036.
    1. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–527. doi: 10.2337/dc08-1865.
    1. Csongrádi É, Nagy B, Fulop T, Varga Z, Karányi Z, Magyar MT, Oláh L, Papp M, Facskó A, Kappelmayer J. et al.Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost. 2011;106:683–692. doi: 10.1160/TH11-01-0030.
    1. Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011;16:86–89. doi: 10.1179/102453311X12902908412110.
    1. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719.
    1. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123:798–813. doi: 10.1161/CIRCULATIONAHA.109.913376.
    1. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis. 2011;219:322–329. doi: 10.1016/j.atherosclerosis.2011.07.011.
    1. Bays HE. Adiposopathy. JAC. 2011;57:2461–2473.
    1. Del Turco S, Navarra T, Gastaldelli A, Basta G. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res. 2011;82:73–76. doi: 10.1016/j.mvr.2011.03.003.
    1. El-Mesallamy HO, Hamdy NM, Salman TM, Mahmoud S. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s) Minerva Endocrinol. 2011;36:163–170.
    1. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, Tavella M, Schreier L, Berg GA. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res. 2009;40:48–53. doi: 10.1016/j.arcmed.2008.10.011.
    1. Dogan A, Tuzun N, Turker Y, Akcay S, Kaya S, Ozaydin M. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia. Coron Artery Dis. 2008;19:559–563. doi: 10.1097/MCA.0b013e3283109079.
    1. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585. doi: 10.1161/01.CIR.0000058700.41738.12.
    1. Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA: J Am Medical Assoc. 2006;295:1935–1940. doi: 10.1001/jama.295.16.1935.
    1. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O. et al.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1–53.
    1. Aspray TJ, Unwin N. Clinical guidelines for older adults with diabetes mellitus. JAMA: J Am Medical Assoc. 2006;296:1839–1840. author reply 1840.
    1. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(Suppl 2):B72–B78.
    1. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S. et al.Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000;153:181–189. doi: 10.1016/S0021-9150(00)00397-X.
    1. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000;2:208–217. doi: 10.1007/s11883-000-0022-3.
    1. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet. 2012;379:507. doi: 10.1016/S0140-6736(12)60216-5.
    1. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle H-J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3. doi: 10.1186/1475-2840-11-3.
    1. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6. doi: 10.1186/1475-2840-11-6.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera